The interim CFO appointment is a temporary measure; monitor for search for a permanent CFO and any further executive departures. The CAO departure is not a red flag alone, but the lack of a permanent CFO may indicate organizational instability typical of a micro-cap biotech.
Price Chart
Executive Summary
Atara Biotherapeutics disclosed the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) and the appointment of Kevin G. Sarney as interim CFO via a consulting agreement with Charles River CFO, Inc. The filing is a routine officer change and carries no material financial information.
Key Facts
- Chief Accounting Officer Yanina Grant-Huerta notified of employment end effective July 17, 2026.
- Kevin G. Sarney appointed interim CFO, principal financial officer, and principal accounting officer on June 26, 2026.
- Sarney, age 61, is a CPA with 25+ years of life science finance experience, serving via a consulting agreement with Charles River CFO, Inc. at an hourly rate.
- No compensation directly to Sarney; consulting agreement can be terminated with 30 days' notice.
- No family relationships or related-party transactions between Sarney and the company.
Financial Impact
No direct financial impact; hourly consulting fees are not disclosed.
Risk Factors
- Prolonged interim CFO arrangement could signal difficulty attracting permanent finance leadership.
- Further executive departures or financial control weaknesses may emerge.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-285498 |
| Document: 0001193125-26-285498-index-headers.html | 0001193125-26-285498 |
| Document: 0001193125-26-285498-index.html | 0001193125-26-285498 |
| Document: 0001193125-26-285498.txt | 0001193125-26-285498 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 26, 2026 14w ago | 8-K | $11.17 $8.93 | ▼ −20.05% | ▼ −24.44% | $9.48 (−15.13%) |
Jun 15, 2026 15w ago | 3 | $9.62 $9.89 | ▲ +2.81% | ▲ +1.81% | $9.48 (−1.46%) |
May 7, 2026 21w ago | 8-K | $9.93 $8.55 | ▼ −13.90% | ▼ −17.73% | $9.48 (−4.53%) |
May 7, 2026 21w ago | Insider Cluster | $9.93 $8.55 | ▼ −13.90% | ▼ −17.73% | $9.48 (−4.53%) |
Apr 24, 2026 23w ago | DEFA14A | $4.99 $8.13 | ▲ +62.83% | ▲ +58.05% | $9.48 (+89.98%) |
Mar 17, 2026 28w ago | S-3 | $5.00 $10.46 | ▲ +109.20% | ▲ +97.67% | $9.48 (+89.60%) |
Mar 12, 2026 29w ago | 8-K | $6.90 $9.92 | ▲ +43.77% | ▲ +33.07% | $9.48 (+37.39%) |
Mar 3, 2026 30w ago | 8-K | $5.42 $10.54 | ▲ +94.46% | ▲ +84.15% | $9.48 (+74.91%) |
Mar 2, 2026 30w ago | Insider Cluster | $4.91 $9.61 | ▲ +95.72% | ▲ +86.40% | $9.48 (+93.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access